NEA Management Company’s Crescent Biopharma CBIO Stock Holding History

NEA Management Company’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-38,350	Closed	-$11.5M	–	42
2024 Q1	$11.5M	Sell	38,350 -9,294	-20%	-$2.78M	0.71%	27
2023 Q4	$11.2M	Hold	47,644	–	–	0.75%	27
2023 Q3	$7.15M	Hold	47,644	–	–	0.55%	29
2023 Q2	$8.29M	Hold	47,644	–	–	0.63%	29
2023 Q1	$6M	Sell	47,644 -42,033	-47%	-$9.46M	0.42%	33
2022 Q4	$27.2M	Sell	89,677 -1,213	-1%	-$179K	1.53%	17
2022 Q3	$5.01M	Hold	90,890	–	–	0.25%	43
2022 Q2	$5.43M	Hold	90,890	–	–	0.28%	42
2022 Q1	$10.4M	Hold	90,890	–	–	0.3%	40
2021 Q4	$13.1M	Hold	90,890	–	–	0.26%	41
2021 Q3	$19.9M	Hold	90,890	–	–	0.24%	38
2021 Q2	$21.1M	Hold	90,890	–	–	0.27%	41
2021 Q1	$27.4M	Hold	90,890	–	–	0.61%	35
2020 Q4	$34.2M	Hold	90,890	–	–	0.9%	27
2020 Q3	$27.9M	Hold	90,890	–	–	1.18%	22
2020 Q2	$34.2M	Hold	90,890	–	–	1.37%	19
2020 Q1	$20.7M	Hold	90,890	–	–	1.08%	20
2019 Q4	$48.1M	Hold	90,890	–	–	2.27%	15
2019 Q3	$39.2M	Hold	90,890	–	–	3.24%	9
2019 Q2	$108M	Hold	90,890	–	–	7.59%	2
2019 Q1	$113M	Hold	90,890	–	–	5.88%	4
2018 Q4	$86.1M	Hold	90,890	–	–	3.41%	7
2018 Q3	$131M	Hold	90,890	–	–	5.65%	5
2018 Q2	$147M	Buy	90,890 +5,049	+6%	+$8.68M	6.87%	4
2018 Q1	$139M	Hold	85,841	–	–	6.2%	4
2017 Q4	$144M	Hold	85,841	–	–	5.97%	2
2017 Q3	$120M	Hold	85,841	–	–	4.21%	4
2017 Q2	$95.8M	Hold	85,841	–	–	3.49%	5
2017 Q1	$46.6M	Hold	85,841	–	–	1.62%	11
2016 Q4	$52.4M	Hold	85,841	–	–	2.08%	10
2016 Q3	$61.4M	Hold	85,841	–	–	2.75%	9
2016 Q2	$62.4M	Hold	85,841	–	–	3.24%	8
2016 Q1	$51.2M	Hold	85,841	–	–	3.4%	9
2015 Q4	$49.1M	Buy	85,841 +90	+0.1%	+$59.7K	3.13%	9
2015 Q3	$48M	Hold	85,751	–	–	3.16%	10
2015 Q2	$68.2M	Hold	85,751	–	–	3.56%	8
2015 Q1	$71.3M	Hold	85,751	–	–	3.23%	10
2014 Q4	$61.7M	Hold	85,751	–	–	2.99%	10
2014 Q3	$59.5M	Hold	85,751	–	–	3.02%	10
2014 Q2	$72.3M	Hold	85,751	–	–	3.39%	10
2014 Q1	$140M	Buy	+85,751	New	+$104M	6.87%	6

Other funds holding CBIO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NEA Management Company's CBIO Position: Q2 2024 in Review

NEA Management Company sold out of Crescent Biopharma (CBIO) in Q2 2024, closing a stake of 38,350 shares — an estimated $11.5M sold.

NEA Management Company first reported a position in CBIO in Q1 2014 and held it in 41 quarters. The position peaked at $147M in Q2 2018. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2024.

NEA Management Company reported no remaining Crescent Biopharma position as of Q2 2024 after selling out during the quarter.
NEA Management Company sold 38,350 Crescent Biopharma shares in Q2 2024, an estimated $11.5M.
NEA Management Company first reported a position in Crescent Biopharma in Q1 2014 and held it in 41 quarters.
NEA Management Company's Crescent Biopharma position peaked at $147M in Q2 2018.
35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2024.

Based on NEA Management Company's 13F filing for Q2 2024, filed 14 Aug 2024.